Jeffrey S. Damrauer, PhD (IMAGE)
Caption
“Two of the likely reasons for limited use of sequencing-directed treatment were the absence of FDA-approved targeted therapies at the time of patient accrual and the approval and use of immune checkpoint inhibitor therapy during the course of the study,” said lead author Jeffrey S. Damrauer, PhD, Bladder Cancer Research Program manager at UNC Lineberger. “We hope, that moving forward, genomically informed decisions can lead to patients being matched with the therapy that gives them a high likelihood to achieve the best outcome.”
Credit
University of North Carolina
Usage Restrictions
None
License
Original content